TUC-S.R.L.
24.4.2024 09:36:30 CEST | Business Wire | Press release
TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tiny™. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries worldwide. A small jewel based on TUC's three technological pillars, mechanical structuring, electronic management and data exchange, designed to also interface with consumer electronics thanks to the integration of USB Type-C technology. TUC.tiny™ becomes the USB of Mobility, a solution that aims to reinvent the interaction between users and vehicles bringing together mobility and everyday life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424672317/en/
TUC dashboard (Photo: Business Wire)
A real blank canvas, which can be transformed and customized countless times thanks to TUC.tiny™ and TUC.technology™, flexibly adapting to every need and preference. With TUC's innovative patented technology, personal devices such as smartphones, tablets, speakers and voice automation systems can be securely integrated. At the same time, automotive-specific elements such as dashboards, switches for driving mode selection and climate control, navigation systems with integrated cameras, harmonize with accessories that can be used both in the car and at home, such as fragrance diffusers and ambient lights.
TUC S.r.l. is at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aims to simplify and revolutionize the concept of vehicles, from a defined product to a definable experience. Distinguishing itself for technological excellence at international level, TUC has achieved significant recognition. With the launch of TUC 3.0 in 2023, the company is setting new standards in the industry by partnering with leading global OEMs.
With TUC.tiny™ and its advanced interface – which includes physical fixing, electrical and data transfer connectivity – any device can be integrated into the modular design of the dashboard, making it immediately operational. This allows users to customize their mobile space with extreme ease and freedom. TUC.tiny™ is designed to support all everyday devices that have a USB Type-C connection. These can be integrated into TUC.tiny™ through a state-of-the-art module. The proposed solution stands out for its ability to blend harmoniously into any part of the vehicle, both inside and outside, ensuring direct and simple installation, both in the production phase and after-sales, eliminating the need to adopt inefficient and unsafe solutions such as suction cups or other impractical and unreliable systems. In addition, the robustness of TUC.tiny™ is ensured by a mechanical or electro-actuated locking system, which introduces the novelty of security offered by NFC technology for reliable control of locking and unlocking functions.
"We are proud of the results achieved thanks to our constant commitment over the last few years," comments Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny™ represents our promise for the future; A vision of a world where technology and mobility come together in personalized experiences, designed around the needs of everyone. With TUC.technology®, we enable a paradigm shift, giving vehicle manufacturers tools to simplify development, engineering, and manufacturing, while enabling new business models that enhance continuous post-production customization. Our goal is that it is not the user who adapts to the life cycle of the vehicle, but that the vehicle can evolve to meet the changing needs of its user. We are thrilled with the results obtained by customers who are experimenting and adopting our technology, testifying to the validity and effectiveness of our work – continues Campana – This is the future that TUC S.r.l. is building: a mobility ecosystem where every innovation is guided by the values of democratization of technology, customization and sustainability, with the ambition to overcome current boundaries and explore new possibilities for a more connected and sustainable society. responsible."
The introduction of TUC.tiny™ is the completion of TUC.technology's offering. It marks a step towards the "democratization" of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives. This isn't just a technological advance; is TUC's invitation to imagine and build together the future of mobility, a world where technology unites us, improving every aspect of our daily journey.
ABOUT TUC.technology
TUC S.r.l. is a Deep-Tech company at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aim to simplify and revolutionize the concept of the vehicle, from a defined product to a definable experience. Distinguishing itself for technological excellence at an international level, TUC has achieved significant recognition, including exhibitions at CES in Las Vegas at the National Automobile Museum and recognition from major newspapers.
With the launch of TUC 3.0, the company is setting new standards in the industry by partnering with leading global OEMs. Learn more at www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424672317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom